Ablynx announces full-year results, shares drop 5%

23 February 2017

Belgian drug developer Ablynx (Euronext Brussels: ABLX) has announced its 2016 financial results, which show the company received just over 85 million euros ($90 million) in grants, a 10% increase on the year before.

Operating costs increased 20% to 114 million euros, and net cash burn stood at 72 million euros, in line with the previously guided range of 65 to 75 million euros. At year’s end, the company’s cash position was 235 million euros, about the same as last year.

In its guidance for the year ahead, Ablynx noted it will hold meetings with regulators in Europe and the USA to discuss its Phase IIb results for vobarilizumab, a candidate rheumatoid arthritis therapy, and plans for a Phase III program.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK